A Study of LY3556050 in Healthy Participants

• Status: Completed
• Trial end date: 2020-08-03
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to learn more about the safety of LY3556050 after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3556050 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive multiple doses of LY3556050 or placebo and will remain in the study for up to 31 days.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Healthy males or females of nonchild bearing potential, as determined by medical history

• Have safety laboratory results within normal references ranges

• Weight at least 50 kilograms (kg)

Exclusion Criteria:

• Have known allergies to LY3556050, iodine, metformin and related compounds

• Abnormal electrocardiogram (ECG) or blood pressure at screening

• Significant history of current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or endocrine disorders

• Show evidence of active renal disease with estimated glomerular filtration rate (GFR) <90 milliliters per minute per 1.73 meters squared